Skandinaviska Enskilda Banken Ab (Publ) Cti Biopharma Corp Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

  • $20.7 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023
SELL
$4.2 - $6.01 $18,484 - $26,450
-4,401 Reduced 4.69%
89,502 $376,000
Q4 2022

Feb 08, 2023
SELL
$4.45 - $6.17 $24,216 - $33,577
-5,442 Reduced 5.48%
93,903 $564,000
Q3 2022

Nov 14, 2022
BUY
$5.36 - $7.43 $532,489 - $738,133
99,345 New
99,345 $578,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email